甲磺酸阿帕替尼联合替吉奥胶囊治疗Ⅲ~Ⅳ期食管癌患者的疗效及对生活质量的影响  

Efficacy of apatinib mesylate combined with S 1 capsule in the treatment of stage III-IV esophageal cancer patients and its influence on quality of life

作　　者：周成[1] 赵磊[1] 李敏[1] ZHOU Cheng;ZHAO Lei;LI Min(Intravenous Drug Dispensing Center,Department of Pharmacy,Nanyang Central Hospital,Nanyang 473000,He'nan,China)

机构地区：[1]南阳市中心医院药学部静脉用药调配中心,河南南阳473000

出　　处：《癌症进展》2024年第21期2362-2365,共4页Oncology Progress

基　　金：南阳市科技发展计划项目(23KJGG100)。

摘　　要：目的 探讨甲磺酸阿帕替尼联合替吉奥胶囊治疗Ⅲ~Ⅳ期食管癌(EC)患者的疗效及对生活质量的影响。方法 将101例Ⅲ~Ⅳ期EC患者按治疗方法的不同分为观察组50例和对照组51例,观察组采用甲磺酸阿帕替尼联合替吉奥胶囊治疗,对照组采用替吉奥胶囊治疗。比较两组患者的临床疗效、血清因子水平、不良反应发生情况及生活质量。结果 观察组患者疾病控制率高于对照组,差异有统计学意义(P﹤0.05)。治疗3个周期后,两组患者血管内皮细胞生长因子受体2(VEGFR2)、血管内皮细胞生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平均降低,且观察组患者VEGFR2、VEGF、bFGF水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。治疗3个周期后,两组患者癌症患者生命质量测定量表(FACT-G)评分均降低,且观察组患者FACT-G评分低于对照组,差异均有统计学意义(P﹤0.05)。结论 甲磺酸阿帕替尼联合替吉奥胶囊治疗Ⅲ~Ⅳ期EC患者效果明显,能调节血清因子水平,改善生活质量。Objective To investigate the efficacy of apatinib mesylate combined with S-1 capsule in the treatment of stage III-IV esophageal cancer(EC)patients and its influence on quality of life.Method A total of 101 patients with stage III-IV EC were divided into observation group(50 cases)and control group(51 cases)according to different treatment methods.The observation group was treated with apatinib mesylate combined with S-1 capsule,and the control group was treated with S-1 capsule.The clinical efficacy,serum factor levels,incidence of adverse reactions and quality of life of the two groups were compared.Result The disease control rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05).After 3 cycles of treatment,the levels of vascular endothelial growth factor receptor 2(VEGFR2),vascular endothelial growth factor(VEGF)and basic fibroblast growth factor(bFGF)were decreased in both groups,and the levels of VEGFR2,VEGF and bFGF in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidences of various adverse reactions between the two groups(P>0.05).After 3 cycles of treatment,the func-tional assessment of cancer therapy-general(FACT-G)scores of both groups were decreased,and the FACT-G score of observation group was lower than that of control group,the differences were statistically significant(P<0.05).Conclusion Apatinib mesylate combined with S-1 capsule has obvious effect on patients with stage III-IV EC,which can regulate the levels of serum factors and improve the quality of life.

关 键 词：食管癌 替吉奥 甲磺酸阿帕替尼 生活质量 

分 类 号：R735.1[医药卫生—肿瘤]